Clinical Trials Logo

Clinical Trial Summary

The pathophysiology of heart failure with preserved ejection fraction (HFpEF) is complex and multifactorial. Chronotropic incompetence has emerged as a crucial mechanism, particularly in elderly patients. Betablockers, drugs with negative chronotropic effect, are commonly used in HFpEF, despite current evidence does not support its routine use in these patients. The aim of this work is to evaluate the effect of betablockers withdrawal in patients with HFpEF and chronotropic incompetence on functional capacity assessed by the peak oxygen consumption at maximal exercise (peakVO2) at 15 and 30 days after the intervention

Clinical Trial Description

This is a prospective, crossover, randomized (1:1) and single center study. After randomization, clinical and cardiac rhythm will be continuously registered during 30 days. The primary endpoint (peakVO2) will be assessed by cardiopulmonary exercise testing (CPET) at 15 and 30-day in both groups. Patients with HFpEF, functional class NYHA II-III, chronic treatment with betablockers, and chronotropic incompetence will be enrolled. A sample size estimation [alfa: 0.05, power: 90%, a 15% loss rate, and delta change of mean peakVO2: +1.2 mL/kg/min (SD±2.5)] of 52 patients would be necessary to test our hypothesis.

In conclusion, optimizing therapy that improve quality of life and autonomy has become a health care priority in HFpEF. The investigators believe this study will add important knowledge for the treatment of a subgroup of HFpEF. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT03871803
Study type Interventional
Source Fundación para la Investigación del Hospital Clínico de Valencia
Contact Julia Seller, MD
Phone 0034961973976
Status Recruiting
Phase Phase 4
Start date October 1, 2018
Completion date March 31, 2020

See also
  Status Clinical Trial Phase
Completed NCT02459626 - Left Ventricular Stiffness vs. Fibrosis Quantification by T1 Mapping in Heart Failure With Preserved Ejection Fraction
Completed NCT02173548 - Interleukin-1 Blockade in HF With Preserved EF Phase 2
Completed NCT03310099 - Unsaturated Fatty Acids Enriched-diet to Improve Cardiorespiratory Fitness, Metabolic Flexibility and Glucose Tolerance in Obese Patients N/A
Completed NCT02638961 - Inspiratory Muscle Training and Functional Electrical Stimulation for Treatment of HFpEF N/A
Not yet recruiting NCT03184311 - High-intensity Interval Training in Heart Failure Patients With Preserved Ejection Fraction N/A
Not yet recruiting NCT03672591 - Renal Hemodynamics in Patients With HFpEF
Recruiting NCT03620526 - Inhaled Iloprost and Exercise Hemodynamics and Ventricular Performance in Heart Failure With Preserved Ejection Fraction Phase 4
Recruiting NCT03541603 - Hemodynamic Evaluation of Levosimendan in Patients With PH-HFpEF Phase 2
Recruiting NCT03624010 - Open-Label Rollover Study of Levosimendan in PH-HFpEF Patients Phase 2
Not yet recruiting NCT03787082 - Chlorhexidine Mouthwash and Oral Nitrate in Adults With Pulmonary Hypertension Phase 1
Recruiting NCT03141567 - LYmphangiogenesis FacTors in Heart Failure States
Recruiting NCT02744339 - Pharmacodynamic Effects of Riociguat in Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction Phase 2
Recruiting NCT03387813 - Hemodynamic-GUIDEd Management of Heart Failure N/A
Recruiting NCT03186833 - The Heart Failure With Preserved Ejection Fraction (HFpEF) Pathophysiology Study. N/A
Completed NCT03289481 - Treatment of HFpEF With Nitrate Supplement N/A
Terminated NCT03195660 - Adherence to ASV Therapy in Heart Failure With Preserved Ejection Fraction Feasibility Study N/A
Recruiting NCT03226652 - Heart Function in Patients Assessed for Sleep Apnoea
Not yet recruiting NCT03549559 - Imaging Histone Deacetylase in the Heart N/A
Recruiting NCT03317314 - Cardiopulmonary Interactions in Patients With Heart Failure N/A
Recruiting NCT02923609 - Cell Therapy in HFpEF Phase 2